Clinical trials: Not Determined
Impotence
Determine If the Stress That Comes With Not Developing an Erection Affects Tadalafil Effects
To determine if patients who are distressed over having problems getting or maintaining an erection react differently to the medication than those who are not stressed over the issue.
- Trial name
- NCT00547599
- Testing
- tadalafil
- Where
- Sweden
- Volunteers
- 659 people
- Sponsor
- Eli Lilly and Company
Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures, Determine Whether BPD With DS or SADI-S as Primary or Revisional Surgery is Superior Than the Other as First Choice for the Superobese
Surgical Innovation for Diabetes Treatment 2
This study aims to understand the enteroendocrine physiological changes in superobese patients submitted to two different bariatric procedures (biliopancreatic diversion with duodenal switch versus single anastomosis…
- Conditions
- Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures, Determine Whether BPD With DS or SADI-S as Primary or Revisional Surgery is Superior Than the Other as First Choice for the Superobese, Determine Whether or Not Revision Surgery is as Effective as Primary Surgery and Understand the Physiological Mechanisms Inherent in These Putative Differences
- Trial name
- SURIDIAB2 (NCT04712409)
- Testing
- Single anastomosis duodeno-ileal bypass, Biliopancreatic diversion with duodenal switch, SADI-S as a revisional procedure
- Where
- 2 sites in Portugal
- Volunteers
- 40 people
- Sponsor
- Hospital de Sao Sebastiao
Lymphoma, Large B-Cell, Diffuse
To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL
Part 1 (Phase Ib) Primary objective: To establish the maximum tolerated dose (MTD) of BI 836826 in combination with GemOx. Secondary objectives: To evaluate pharmacokinetics of BI 836826 when given in combination with GemOx and…
- Trial name
- NCT02624492
- Testing
- BI 836826, GemOx, Rituximab
- Where
- 7 sites in Belgium, Italy and 1 more
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis C
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
The purpose of this study is to estimate the rate of sustained virologic response (SVR) SVR12, where SVR12 is defined as HCV RNA < LOQ (detectable or undetectable) 12 weeks post-treatment in Genotype 1 \& Genotype 4 treatment…
- Trial name
- NCT01455090
- Testing
- BMS-650032, BMS-790052, BMS-791325
- Where
- 32 sites in United States, France and 1 more
- Volunteers
- 320 people
- Sponsor
- Bristol-Myers Squibb
Not Determined
Validation of a Food Frequency Questionnaire: VioScreen
The purpose of this study is to learn more about how well a questionnaire about food intake works. The study team will compare questionnaire responses to several other measurements of food intake.
- Trial name
- NCT05762718
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
This phase II trial studies the effects of luspatercept with or without hydroxyurea in treating patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring…
- Trial name
- NCT05005182
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.
- Trial name
- FIRST (NCT00689936)
- Testing
- Lenalidomide and low-dose dexamethasone, Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles, Melphalan, Prednisone and Thalidomide
- Where
- 288 sites in United States, Australia and 17 more
- Volunteers
- 1,623 people
- Sponsor
- Celgene
Metastatic Renal Cell Carcinoma
Pazopanib in Second-line Therapy in Renal Cell Carcinoma
The principal aim of the study is to determine the objective response rate that offers the second-line treatment with pazopanib in patients with carcinoma of advanced renal cells that have progressed or that have not tolerated…
- Trial name
- NCT01577784
- Testing
- Pazopanib
- Where
- 10 sites in Spain
- Volunteers
- 27 people
- Sponsor
- Associació per a la Recerca Oncologica, Spain
Solid Tumors
Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors
The investigators plan to study the determination of the dose and the combination of antiangiogenic effect of dovitinib and cytotoxic activity of weekly paclitaxel in different types of malignant tumors.
- Trial name
- NCT01548924
- Testing
- Dovitinib, Dovitinib + Paclitaxel
- Where
- 3 sites in Spain
- Volunteers
- 13 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Not Determined
First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants
This study will evaluate the safety, tolerability, and pharmacokinetics of BGB-23339 and food effects in healthy participants
- Trial name
- NCT05093270
- Testing
- BGB-23339
- Where
- 3 sites in Australia, China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- BeiGene
Critical Illness
Code Status Video in the Intensive Care Unit: Video Assisted Patient Education
This is a single-center, randomized control trial of a code status video as an educational tool in the intensive care unit. Subjects are stratified by patient or surrogate and are randomized to either watch an educational video…
- Trial name
- NCT01610076
- Testing
- Code Status Video
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- Mayo Clinic
HIV Infections
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
This is a multicentre study carried out in participants living with human immunodeficiency virus type 1 (HIV-1) who have not previously been treated with any antiretroviral therapies.
- Trial name
- VOLITION (NCT05917509)
- Testing
- DTG/3TC, Cabotegravir (CAB) LA, Rilpivirine (RPV) LA
- Where
- 47 sites in United States, Argentina and 7 more
- Volunteers
- 171 people
- Sponsor
- ViiV Healthcare
Not Determined
A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers
This is a single-center, open-label, parallel group study designed to investigate the effect of CYP3A induction and inhibition following multiple doses of phenytoin (Part A) and itraconazole (Part B), respectively, on the…
- Trial name
- NCT06543043
- Testing
- Phenytoin, Itraconazole, sonrotoclax
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BeiGene
HER2 Negative Breast Cancer Not Immediately Operated
Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)
Women aged 70 years or older, newly diagnosed for locally advanced unilateral breast cancer, with a histological diagnosis of invasive mammary carcinoma, positive hormone receptors, HER2 status Negative, not immediately operable…
- Trial name
- CALHYS (NCT05664893)
- Testing
- Ribociclib Oral Tablet
- Where
- France
- Sponsor
- Centre Antoine Lacassagne
Blood Transfusion, Blood Transfusion, Autologous
A Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel Surgery
The purpose of this study is to determine whether epoetin alfa will enable self-donation of at least 4 units of blood during the 2-week period before surgery (which is a shorter period of time than the conventional 3-week blood…
- Conditions
- Blood Transfusion, Blood Transfusion, Autologous, Orthopedic Procedures, Orthopedic Surgery
- Trial name
- NCT00270075
- Testing
- epoetin alfa
- Volunteers
- 80 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid…
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
- Trial name
- NCT05554406
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 227 sites in United States, Canada and 1 more
- Volunteers
- 335 people
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic Syndromes (MDS)
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Alvocidib, a cyclin-dependent kinase 9 (CDK 9) inhibitor, in time-sequential therapy demonstrated significant clinical activity in secondary AML patients with prior MDS.
- Trial name
- NCT03593915
- Testing
- Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
- Where
- 12 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sumitomo Pharma America, Inc.
Not Determined
First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers
This is a Phase 1, First-In-Human study evaluating the safety and tolerability of single and multiple ascending oral doses of IRL757 in healthy volunteers.
- Trial name
- NCT06493045
- Testing
- IRL757
- Where
- Sweden
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Integrative Research Laboratories AB
Attention Deficit Disorder, Attention Deficit Disorder (ADD)
The Primary Objective of This Study is to Determine Whether Positively Framed Information (PFI) on Side Effects, Compared to Negatively Framed and Extensive Information (NFI) Can Reduce the Number and Severity of Reported Adverse Events Caused by ADHD Medication in Children Aged 7 to 17 Years.
The goal of this randomized controlled care evaluation is to determine whether positively framed and concise information (PFI), compared to negatively framed and extensive information (NFI) about adverse events can reduce the…
- Conditions
- Attention Deficit Disorder, Attention Deficit Disorder (ADD), Attention Deficit Disorder with Hyperactivity, ADHD
- Trial name
- NOVA (NCT06797570)
- Testing
- Communication Strategy for Side Effect Counseling in ADHD Treatment
- Volunteers
- 130 people
- Sponsor
- St. Antonius Hospital
Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia and Myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap…
- Conditions
- Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified, Recurrent Atypical Chronic Myeloid Leukemia
- Trial name
- NCT05549661
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Onvansertib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic